About
The group’s primary goal is to study the acute pharmacological effects and toxicity caused by substances of abuse in humans. This objective encompasses the evaluation of abuse potential and the consequences of chronic use in substance use disorders and addiction.
The members of the group are mostly physicians at the Germans Trias i Pujol Hospital, responsible for daily patient care.
Keywords: Psychoactive substances, drugs of abuse, pharmacological effects.
_1687256412.jpg)
Group Leader
Research lines
Evaluation of the acute effects of new psychoactive substances (synthetic cathinones such as methylone, pyrovalerone derivatives, and others), and classical psychostimulants (MDMA, amphetamines and cocaine). Including experimental and observational studies
Evaluation of the acute effects of binge alcohol consumption in young people and its combination with other substances (cannabis, energy drinks). Including experimental and observational studies
Evaluation of the effects of natural and synthetic cannabinoids, including cannabis and its components, and its therapeutic use (medicinal cannabis). Including experimental and observational studies
Pharmacogenomics and substance use, including drug of abuse and medicines. Influence of genetic polymorphism in the effects and pharmacokinetics of drugs
Active projects
Proyecto iPHARMGx: Estudio colaborativo nacional para evaluar la efectividad y eficiencia de la implementación de biomarcadores Farmacogenéticos mediante una estrategia de genotipado anticipado en el SNS
PI: Borovia A. HUGTP-IGTP investigator: Magí Farré
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PMP22/00055
Start date: 2023
End date: 2025
Consumo de alcohol en atracón (binge drinking): perspectiva de género
PI: Magí Farré
Funding agency: Ministerio de Sanidad
Agency code: 2022I045
Start date: 2023
End date: 2024
Farmacología humana de diferentes preparados de cannabis administrados por diferentes vías y la influencia del género
PI: Esther Papaseit
Funding agency: Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación
Agency code: PI20/00879
Start date: 2021
End date: 2023
Plataformas ISCIII de apoyo a la I+D+I en Biomedicina y Ciencias de la Salud: Soporte para la investigación clínica
PI: Magí Farré
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PT20/00018
Start date: 2021
End date: 2023
Farmacología humana de la catinona sintética metilendioxipirovalerona (MDPV) y su interacción con alcohol
PI: Clara Pérez Mañá
Funding agency: Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación
Agency code: PI20/00879
Start date: 2021
End date: 2023
Scientific publications
Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022 Mar;10(3):278-288. DOI: 10.1016/s2213-2600(21)00545-2
Poyatos L, Lo Faro AF, Berardinelli D, Sprega G, Malaca S, Pichini S, Huestis MA, Papaseit E, Pérez-Mañá C, Busardò FP, Farré M. Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans. Int J Mol Sci. 2022 Nov 23;23(23):14636. DOI: 10.3390/ijms232314636
Moltó J, Bailón L, Pérez-Mañá C, Papaseit E, Miranda C, Martín S, Mothe B, Farré M. Absence of drug-drug interactions between γ-hydroxybutyric acid (GHB) and cobicistat. J Antimicrob Chemother. 2021 Dec 24;77(1):181-184. DOI: 10.1093/jac/dkab359
Additional information
Activity is based in different types of studies for the evaluation of the acute and chronic effects. The study design include clinical trials, observational studies and summary of evidence (systematic reviews and meta-analysis).
Contact
Magí Farré Albaladejo
(+34) 93 497 88 65 extn. 3710